We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Thermo Fisher Scientific - Direct Effect Media

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

First-Ever Test Indicates Risk of Preeclampsia Months Before Symptoms Occur

By HospiMedica International staff writers
Posted on 05 May 2022
Print article
Image: Mirvie RNA platform predicts pregnancy complications months before they occur (Photo courtesy of Mirvie)
Image: Mirvie RNA platform predicts pregnancy complications months before they occur (Photo courtesy of Mirvie)

Unexpected complications affect one in five pregnancies, with large economic costs and lifelong health consequences for expecting parents and babies. They often leave families in a state of crisis and are a primary driver of childhood morbidity and mortality, frequently resulting in neonatal intensive care for the baby’s survival. Pregnancy complications can double or even quadruple a mom’s lifetime risk of cardiovascular disease, regardless of how early the baby is born. Yet, women, expecting parents and doctors lack a reliable way to detect complications before symptoms appear. Now, the first test designed to indicate risk of preeclampsia months before symptoms occur has the potential to address a leading cause of maternal mortality that impacts millions of pregnancies each year.

The Mirvie Preeclampsia Test from Mirvie (South San Francisco, CA, USA) indicates a woman’s individualized risk of developing preeclampsia before symptoms occur. The test is powered by the proprietary Mirvie RNA platform, which is designed to predict the risk of unexpected complications by revealing the underlying biology of each pregnancy. The proprietary Mirvie RNA platform combines revolutionary analysis of tens of thousands of RNA messages from the baby, the placenta and the mom, with machine learning. The platform opens a new window into pregnancy health for expecting parents to act and their doctors to intervene before unexpected complications become a crisis.

Landmark research provides preliminary evidence that the Mirvie RNA platform can identify 75% of women who go on to develop preeclampsia months before symptoms occur. Additional research shows the platform can predict 76% of early preterm birth cases and identify distinct biological pathways driving its development. The Mirvie Preeclampsia Test is the first test for the early identification of preeclampsia risk months before any clinical presentation of symptoms to receive FDA Breakthrough Device designation. With this designation, Mirvie will continue ongoing clinical research to further validate the Mirvie Preeclampsia Test performance and improve the understanding of preeclampsia.

“Pregnancy health must become proactive, preventive, and personalized for the wellbeing of expecting parents and babies,” said Maneesh Jain, Ph.D., Co-Founder and CEO of Mirvie. “Ever-growing clinical evidence shows the Mirvie RNA platform is charting a new course to make that possible

“Prenatal care as we know it in the United States was first developed to primarily diagnose preeclampsia, yet these protocols have not changed in over fifty years,” said Eleni Tsigas, CEO of the Preeclampsia Foundation. “Moms and babies deserve more – there is an urgent need for innovation that not only identifies the risk of developing preeclampsia early, but also helps bring pregnancy health into the 21st century.”

Related Links:
Mirvie 


Print article

Channels

Critical Care

view channel
Image: Triage Cardiac Panel is a rapid, POC fluorescence immunoassay used with Triage MeterPro (Photo courtesy of Quidel)

Quidel Triage Cardiac Panel Facilitates Rapid POC Diagnosis of Chest Pain Patients in ED

Chest and abdominal pain are the most common reasons that persons aged 15 years and over visit the emergency department (ED). Because both emergency and non-emergency care are provided, symptoms vary widely... Read more

Surgical Techniques

view channel
Image: A minimally invasive diagnostic biomarker strategy has proven successful in detecting early esophageal cancer (Photo courtesy of Pexels)

Minimally Invasive Device Combined With Molecular Biomarkers Detects Early Esophageal Cancer

Esophageal cancer remains the sixth-most common cause of cancer death worldwide, claiming the lives of more than half a million people annually. Esophageal squamous cell carcinoma (ESCC) comprises 80%... Read more

Patient Care

view channel
Image: Future wearable health tech could measure gases released from skin (Photo courtesy of Pexels)

Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases

Most research on measuring human biomarkers, which are measures of a body’s health, rely on electrical signals to sense the chemicals excreted in sweat. But sensors that rely on perspiration often require... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.